Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMYHealthcare · Biotechnology
+1.97%$33.11
CLOSED · Nov 6Prev close$32.47+1.97%Close$33.11-0.33%AH close$33.00
AH$33.00-0.33%vs close
Mkt Cap$1.94B
Float45.73M
O/S58.72M
VOL787K sh
$ Vol$26M
RVOL0.64×
Inst Own96.0%
SI11.8%
Dilution
Financials Summary
Revenue$868.45M
Net Income$158.69M
Total Assets$1.27B
Free Cash Flow$347.89M
Debt & Equity
Debt 22%
Equity 78%
Total Debt$239.58M
Total Equity$870.22M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in HRMY's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$1.27B
Liabilities$401.41M
Accounts Receivable$96.79M
Accounts Payable$17.69M
Inventory$5.36M
PP&E (Net)$5.34M
Goodwill$0
Intangible Assets$89.42M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M | $6M | $0 |
| YoY Growth | 21.5% | 22.8% | 32.9% | 43.4% | 91.2% | 2564.6% | - | - |
| Cost of Revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M | $1.58M | $184K |
| Gross Profit | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M | $132M | $4.42M | -$184K |
| Gross Margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% | - |
| Research and Development | $189.59M | $145.82M | $76.06M | $70.89M | $30.37M | $19.45M | $69.59M | $12.37M |
| Selling, General, and Administrative | $272.05M | $221.27M | $192.69M | $163.3M | $132.03M | $95.57M | $80.73M | $29.07M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $461.64M | $367.09M | $268.76M | $234.19M | $162.39M | $115.02M | $150.32M | $41.44M |
| Operating Income (EBIT) | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M | -$145.9M | -$41.44M |
| Operating Margin | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | 10.6% | -2433.8% | - |
| Interest Expense | $14.65M | $17.5M | $23.76M | $18.8M | $24.19M | $28.22M | $6.07M | $0 |
| Interest Income | $21.92M | $18.54M | $14.73M | $3.13M | $224K | $0 | $0 | $0 |
| Other Income (Expense) | $6.59M | $978K | -$18.63M | -$15.5M | -$50.1M | -$53.93M | -$6.07M | $1.54M |
| Income Before Tax (EBT) | $215.06M | $191.8M | $173.4M | $104.69M | $37.43M | -$36.94M | -$151.98M | -$39.9M |
| Income Tax Expense | $56.38M | $46.31M | $44.54M | -$76.78M | $2.83M | $0 | $0 | $0 |
| Net Income | $158.69M | $145.49M | $128.85M | $181.47M | $34.6M | -$36.94M | -$151.98M | -$39.9M |
| Net Income Margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% | - |
| Supplementary Data | ||||||||
| EPS | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 | -2.94 | -1.42 |
| Diluted EPS | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 | -1.10 | -2.94 | -1.42 |
| Weighted Average OS | 57.49M | 56.88M | 59.47M | 59.17M | 57.53M | 56.89M | 63.68M | 49.24M |
| EBITDA | $255.05M | $233.41M | $221.51M | $146.87M | $80.46M | $1.51M | -$142.69M | -$41.26M |
| EBITDA Margin | 29.4% | 32.7% | 38.1% | 33.5% | 26.3% | 0.9% | -2380.2% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $752.5M | $453M | $311.66M | $243.78M | $234.31M | $228.63M | $24.46M | $83.52M |
| Short-Term Investments | $22.84M | $14.19M | $41.8M | $79.33M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $775.34M | $467.19M | $353.46M | $323.12M | $234.31M | $228.63M | $24.46M | $83.52M |
| Accounts Receivable | $96.79M | $83.03M | $74.14M | $54.74M | $34.84M | $22.18M | $4.25M | $0 |
| Inventory | $5.36M | $7.2M | $5.36M | $4.3M | $4.43M | $3.82M | $1.09M | $0 |
| Other Current Assets | $13.52M | $8.12M | $5.54M | $8.79M | $3.22M | $1.3M | $261K | $2.46M |
| Total Current Assets | $907.01M | $579.25M | $451.07M | $400.29M | $284.44M | $262.89M | $31.5M | $86.68M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $5.34M | $3.38M | $371K | $573K | $4.12M | $938K | $1.33M | $1.58M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $89.42M | $113.26M | $137.11M | $160.95M | $143.92M | $162.34M | $72.19M | $0 |
| Long-Term Investments | $107.4M | $108.87M | $72.17M | $22.57M | $0 | $0 | $0 | $500K |
| Deferred Tax Assets | $149.7M | $0 | $144.16M | $85.94M | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $12.76M | $194.43M | $6.57M | $3.55M | $967K | $902K | $1.69M | $522K |
| Total Long-Term Assets | $364.62M | $419.95M | $360.38M | $273.58M | $149M | $164.18M | $75.21M | $2.6M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.27B | $999.2M | $811.45M | $673.87M | $433.44M | $427.07M | $106.7M | $89.28M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $17.69M | $13.74M | $17.73M | $3.79M | $1M | $2.56M | $6.36M | $1.46M |
| Short-Term Debt | $86.89M | $16.25M | $15M | $2M | $2M | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $129.1M | $4.35M | $107.3M | $1.62M | $0 | $100.31M | $753K | $313K |
| Total Current Liabilities | $252.13M | $175.08M | $163.78M | $78.88M | $53.77M | $134.54M | $19.89M | $7.23M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $148.18M | $163.02M | $178.57M | $189.65M | $189.98M | $194.25M | $97.95M | $324.2M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $262K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$324.46M |
| Other Long-Term Liabilities | -$3.41M | $1.13M | $2.11M | $2.5M | $777K | $1.1M | $450K | -$323.68M |
| Total Long-Term Liabilities | $149.28M | $164.96M | $180.68M | $192.15M | $193.16M | $195.35M | $98.4M | $523K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $401.41M | $340.05M | $344.46M | $271.03M | $246.94M | $329.89M | $118.29M | $7.75M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $411.28M | $324.2M |
| Common Stock | $1K | $1K | $1K | $1K | $1K | $1K | $0 | $1K |
| Retained Earnings | $160.9M | $2.22M | -$143.28M | -$272.13M | -$453.6M | -$488.19M | -$422.86M | -$242.67M |
| Comprehensive Income & Other | $346K | $66K | $2K | -$151K | $0 | $0 | $0 | -$2K |
| Other Stockholders' Equity | $709.31M | $656.94M | $610.27M | $674.97M | $640.1M | $585.37M | $411.28M | $324.2M |
| Total Equity | $870.22M | $659.15M | $466.99M | $402.84M | $186.51M | $97.18M | -$11.59M | $81.53M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.27B | $999.2M | $811.45M | $673.87M | $433.44M | $427.07M | $106.7M | $89.28M |
| Supplementary Data | ||||||||
| Total Debt | $239.58M | $181.41M | $193.57M | $191.65M | $195.74M | $194.25M | $97.95M | $324.2M |
| Net Debt | -$512.92M | -$271.6M | -$118.09M | -$52.14M | -$38.56M | -$34.38M | $73.49M | $240.68M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | $158.69M | $145.49M | $128.85M | $181.47M | $34.6M | -$36.94M | -$151.98M | -$39.9M |
| Depreciation & Amortization | $25.34M | $24.11M | $24.36M | $23.39M | $18.84M | $10.24M | $3.21M | $184K |
| Deferred Income Tax | $0 | -$29.3M | -$13.42M | $0 | $0 | $25.75M | $0 | $0 |
| Stock-Based Compensation | $44.9M | $42.6M | $31.7M | $26.91M | $16.11M | $4.69M | $9.91M | $1.08M |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | -$13.75M | -$8.89M | -$19.4M | -$19.9M | -$12.67M | -$17.92M | -$4.25M | $0 |
| Inventory | $1.84M | -$1.83M | -$1.07M | $135K | -$609K | -$2.73M | -$1.09M | $0 |
| Accounts Payable | $3.95M | -$5.38M | $8.95M | $0 | $0 | -$3.8M | $0 | -$610K |
| Other Working Capital | $99.78M | $8.79M | $46.55M | $12.87M | $15.46M | $12.83M | $8.74M | $446K |
| Total Working Capital Change | $91.82M | -$7.32M | $35.03M | -$6.89M | $2.19M | -$11.63M | $3.39M | -$164K |
| Other Non-Cash Items | $27.46M | $44.23M | $12.85M | -$80.4M | $26.83M | $4.91M | $60.03M | $2.06M |
| Net Cash from Operating | $348.2M | $219.82M | $219.39M | $144.47M | $98.56M | -$2.98M | -$75.44M | -$38.8M |
| Investing Activities | ||||||||
| Capital Expenditures | -$19.56M | -$1.15M | -$312K | -$172K | -$298K | -$2M | -$149K | -$1.34M |
| Acquisitions | $0 | -$33.07M | -$36.97M | $0 | $0 | -$2M | $0 | $0 |
| Purchases of Investments | -$86.15M | -$105.29M | -$127.47M | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $81.06M | $98.53M | $118.31M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$15M | -$26.5M | $0 | -$141.66M | -$100M | $2M | -$127M | $0 |
| Net Cash from Investing | -$39.65M | -$67.48M | -$46.44M | -$141.83M | -$100.3M | -$2M | -$127.15M | -$1.34M |
| Financing Activities | ||||||||
| Debt Repaid | $16.25M | $15M | $1.25M | $2M | $500K | -$79.42M | -$100M | - |
| Common Stock Issuance | $10.21M | $6.5M | $0 | $0 | $0 | $147.63M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | -$100M | $0 | $0 | -$167K | $0 | -$3.2M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$3M | -$2.5M | -$3.79M | $8.84M | $7.92M | $129.93M | $43.77M | -$185K |
| Net Cash from Financing | -$9.05M | -$11M | -$105.55M | $6.84M | $7.42M | $209.16M | $143.77M | $21.61M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $299.5M | $141.34M | $67.4M | $9.47M | $5.68M | $204.17M | -$58.82M | -$18.53M |
| Supplementary Data | ||||||||
| Operating Cash Flow | $348.2M | $219.82M | $219.39M | $144.47M | $98.56M | -$2.98M | -$75.44M | -$38.8M |
| Capital Expenditure | -$310K | -$1.15M | -$312K | -$172K | -$298K | -$2M | -$149K | -$1.34M |
| Free Cash Flow | $347.89M | $218.67M | $219.07M | $144.29M | $98.26M | -$4.99M | -$75.58M | -$40.14M |
| Cash at Beginning | $453M | $311.93M | $244.53M | $235.06M | $229.38M | $25.21M | $84.02M | $102.55M |
| Cash at End | $752.5M | $453.27M | $311.93M | $244.53M | $235.06M | $229.38M | $25.21M | $84.02M |